Drug profile · INN
baxdrostat
BAXFENDY
baxdrostat (BAXFENDY) is an FDA-listed pharmaceutical active ingredient. Route of administration: oral. Current US regulatory status: approved.
Drug details — baxdrostat
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 0
- Programs
- 10
- Data quality
- 0.84
Quick answer
baxdrostat (BAXFENDY) is an FDA-listed pharmaceutical active ingredient. Route of administration: oral. Current US regulatory status: approved.
Key facts
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Recent coverage
FDA Approves Baxdrostat (Baxfendy) as First Aldosterone Synthase Inhibitor for Uncontrolled Hypertension
The FDA has approved AstraZeneca's baxdrostat (Baxfendy), the first-in-class aldosterone synthase inhibitor, for adults with uncontrolled hypertension. This landmark approval offers a new therapeutic option for patients with difficult-to-treat hypertension.
FDA Approves AstraZeneca’s Baxdrostat for Hypertension
The FDA has approved AstraZeneca's baxdrostat for treating hypertension, marking a significant milestone in hypertension management. This article explores the implications for pharmaceutical stakeholders.
Pipeline programs
Frequently asked questions
What is baxdrostat?
baxdrostat (BAXFENDY) is an FDA-listed pharmaceutical active ingredient. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for baxdrostat?
BAXFENDY is a marketed brand name for baxdrostat. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of baxdrostat?
baxdrostat has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.